Voyager Therapeutics, Inc. (NASDAQ:VYGR) is in the process of developing its anti-Tau antibody VY7523 for the treatment of patients with Alzheimer's Disease [AD] in a phase 1a single-ascending ...
Some results have been hidden because they may be inaccessible to you